Vancouver, British Columbia March 31, 2015 Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,980,279 relating to the use of immunotherapies derived from components of E. coli to treat Crohn’s disease.
The allowed claims of the patent, which issued on March 17, 2015, cover the use of E. coli components as SSIs to stimulate an immune response to treat Crohn’s disease. This latest patent builds on Qu Biologics’ patent portfolio covering SSI treatment of a range of inflammatory disorders and cancers.
Dr. Hal Gunn, Chief Executive Officer of Qu Biologics, commented, We are very pleased to have been granted this important U.S. patent that covers our novel Crohn’s treatment in clinical use in our randomized, placebo-controlled clinical trial. Dr. Gunn added, Our SSIs aim to address the underlying immunological causes of many chronic inflammatory diseases, representing a novel treatment approach that restores the body’s own immune response. We will continue to further strengthen our patent position as we advance our clinical trials in inflammatory bowel disease.